Biochemical and structural characteristics of crizotinib-resistant ALK mutants.

被引：0
|
作者：
Timofeevski, Sergei [1 ]
Liu, Wei [1 ]
Deng, Ya-Li [1 ]
Brooun, Alex [1 ]
Bergqvist, Simon [1 ]
Karlicek, Shannon [1 ]
Murray, Brion [1 ]
Bolanos, Ben [1 ]
McTigue, Michele [1 ]
机构：
[1] Pfizer Inc, San Diego, CA USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-4456
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4456
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
    Ceccon, Monica
    Mologni, Luca
    Bisson, William
    Scapozza, Leonardo
    Gambacorti-Passerini, Carlo
    MOLECULAR CANCER RESEARCH, 2013, 11 (02) : 122 - 132
  • [2] Alectinib in crizotinib-resistant, ALK-positive NSCLC
    Jassem, Jacek
    LANCET ONCOLOGY, 2016, 17 (02): : 134 - 135
  • [3] Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
    Zhang, Sen
    Wang, Frank
    Keats, Jeffrey
    Zhu, Xiaotian
    Ning, Yaoyu
    Wardwell, Scott D.
    Moran, Lauren
    Mohemmad, Qurish K.
    Anjum, Rana
    Wang, Yihan
    Narasimhan, Narayana I.
    Dalgarno, David
    Shakespeare, William C.
    Miret, Juan J.
    Clackson, Tim
    Rivera, Victor M.
    CHEMICAL BIOLOGY & DRUG DESIGN, 2011, 78 (06) : 999 - 1005
  • [4] ALECTINIB IS ACTIVE IN CRIZOTINIB-RESISTANT ALK-REARRANGED NSCLC
    Gadgeel, S. M.
    Gandhi, L.
    Riely, G. J.
    Chiappori, A. A.
    West, H. L.
    Azada, M. C.
    CANCER DISCOVERY, 2014, 4 (10) : 1113 - 1113
  • [5] A new option for crizotinib-resistant ALK-rearranged NSCLC
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (06) : 573 - 573
  • [6] Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants
    Chen, Wenteng
    Guo, Xiao
    Zhang, Can
    Ke, Di
    Zhang, Guolin
    Yu, Yongping
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 183
  • [7] Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
    Fontana, Diletta
    Ceccon, Monica
    Gambacorti-Passerini, Carlo
    Mologni, Luca
    CANCER MEDICINE, 2015, 4 (07): : 953 - 965
  • [8] Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations
    Tu, Jing
    Song, Li Ting
    Liu, Rui Rui
    Zhai, Hong Lin
    Wang, Juan
    Zhang, Xiao Yun
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (01) : 562 - 574
  • [9] Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations
    Liu, Xile
    Zhang, Lu
    Wan, Haiwen
    Zhu, Zhenzhen
    Jin, Jing
    Qin, Yuxin
    Mao, Weifeng
    Yan, Kang
    Fang, Douglas
    Jiang, Wen
    Hu, Lihong
    Chen, Jinhua
    Chen, Kevin
    Chen, Shuhui
    Li, Jian
    Zhao, Shuyong
    Zheng, Shansong
    Zhang, Long
    Ding, Charles Z.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 66
  • [10] AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions.
    Squillace, Rachel M.
    Anjum, Rana
    Miller, David
    Vodala, Sadanand
    Moran, Lauren
    Wang, Frank
    Clackson, Tim
    Garner, Andrew P.
    Rivera, Victor M.
    CANCER RESEARCH, 2013, 73 (08)
12345